logo
ResearchBunny Logo
Abstract
Pancreatic cancer (PC) has a grim prognosis, and new therapies are urgently needed. This study investigated the antitumor activity of Oba01, an antibody-drug conjugate (ADC) targeting death receptor 5 (DR5), in preclinical PC models. Oba01 demonstrated potent in vitro and in vivo antitumor activity in DR5-positive PC cells and xenografts, mediated through apoptosis induction, G2/M phase growth arrest, bystander effect, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC). A synergistic effect was observed when Oba01 was combined with gemcitabine, enhancing antiproliferative activity both in vitro and in vivo. These results suggest Oba01 holds promise as a novel therapeutic approach for DR5-expressing PC.
Publisher
Cell Death and Disease
Published On
Jan 01, 2023
Authors
Chao Zheng, Dongdong Zhou, Weisong Li, Yanhui Duan, Minwen Xu, Jie Liu, Jingpei Cheng, Youban Xiao, Han Xiao, Tao Gan, Jianmin Liang, Dexian Zheng, Liefeng Wang, Shuyong Zhang
Tags
pancreatic cancer
antibody-drug conjugate
Oba01
DR5
synergistic effect
apoptosis
gemcitabine

Related Publications

Explore these studies to deepen your understanding of the subject.

Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients
Medicine and Health

Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients

J. Kong, H. Lee, et al.

Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial
Medicine and Health

Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial

S. Mukherjee, C. N. Hurt, et al.

A comparative study of COVID-19 transcriptional signatures between clinical samples and preclinical cell models in the search for disease master regulators and drug repositioning candidates
Medicine and Health

A comparative study of COVID-19 transcriptional signatures between clinical samples and preclinical cell models in the search for disease master regulators and drug repositioning candidates

H. Chapola, M. A. D. Bastiani, et al.

Open Access Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
Medicine and Health

Open Access Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer

Y. Harada, A. Sato, et al.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs—just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny